- Products
Products
Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
- Clinical Resources
Clinical Resources
Diurnal is dedicated to developing new treatments to aid lifelong treatment for rare and chronic endocrine conditions
- R&D
R&D
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
- Transparency
Transparency
Diurnal is committed to transparency in its interactions. Diurnal commits to following the Association of British Pharmaceutical Industry (ABPI) Code of Practice which has clear requirements for transparency.
- Careers
Careers
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
- Awards
Awards
A limited number of awards is available each year, and all applications will be judged objectively by an independent panel.
Click here to view the UKGB/UKNI Prescribing information
Click here to view the Alkindi administration video
Alkindi® (hydrocortisone granules in capsules for opening) is Diurnal’s first commercialised medicine and is indicated as replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to less than 18 years old)1. Alkindi was approved through the centralised paediatric use marketing authorisation (PUMA) route in the European Union in 2018. Prior to Alkindi, most treatment of paediatric adrenal insufficiency in the UK relied on parents preparing child-appropriate doses from adult hydrocortisone formulations, a practice which yields highly variable doses and can be stressful for parents and caregivers2,3.
Alkindi is an immediate-release hydrocortisone preparation that has been specifically designed to meet the dosing needs of paediatric patients with adrenal insufficiency for whom, prior to Alkindi, no licensed, child-friendly products were available. Alkindi is manufactured using commercially proven technology in four doses: 0.5mg, 1mg, 2mg and 5mg, in order to give maximum flexibility to clinicians in tailoring the treatment to the child. Taste-masking excipients that are acceptable for paediatric use eliminate the bitter taste of hydrocortisone, potentially increasing compliance. Alkindi has a shelf life exceeding two years which is significantly longer than that of existing unlicensed hydrocortisone products.
1. Alkindi Summary of Product Characteristics
2. Watson C, Webb EA, Kerr S, Davies JH, Stirling H, Batchelor H. How close is the dose? Manipulation of 10mg hydrocortisone tablets to provide appropriate doses to children. Int J Pharm 2018; 545:57-63
3. Simpson A, Ross R, Porter J, Dixon S, Whitaker MJ, Hunter A. Adrenal Insufficiency in Young Children: A Mixed Methods Study of Parents' Experiences. J Genet Couns 2018; 27:1447-1458
